Microbot Medical Inc. (NASDAQ:MBOT) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Microbot Medical Inc. (NASDAQ:MBOT) have received an average rating of “Moderate Buy” from the five brokerages that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $7.50.

Several research analysts have recently commented on the company. Wall Street Zen upgraded Microbot Medical from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Microbot Medical in a report on Friday, April 10th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Microbot Medical in a research report on Tuesday, April 14th. Finally, B. Riley Financial began coverage on shares of Microbot Medical in a report on Tuesday, February 10th. They issued a “buy” rating on the stock.

Microbot Medical Stock Up 0.6%

Shares of MBOT stock opened at $1.74 on Thursday. Microbot Medical has a 52-week low of $1.60 and a 52-week high of $4.67. The stock has a market cap of $116.88 million, a price-to-earnings ratio of -6.69 and a beta of 1.06. The firm’s 50-day moving average is $2.32 and its 200-day moving average is $2.20. The company has a debt-to-equity ratio of 0.01, a quick ratio of 21.93 and a current ratio of 22.59.

Microbot Medical (NASDAQ:MBOT) last announced its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. The business had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.30 million. Sell-side analysts predict that Microbot Medical will post -0.31 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Beacon Capital Management LLC raised its holdings in Microbot Medical by 37.5% in the 3rd quarter. Beacon Capital Management LLC now owns 22,000 shares of the biotechnology company’s stock valued at $67,000 after acquiring an additional 6,000 shares during the period. Cetera Investment Advisers boosted its holdings in shares of Microbot Medical by 38.8% during the fourth quarter. Cetera Investment Advisers now owns 29,313 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 8,201 shares during the period. Cornerstone Advisory LLC bought a new stake in shares of Microbot Medical during the third quarter worth approximately $30,000. Zacks Investment Management acquired a new position in shares of Microbot Medical in the third quarter valued at approximately $33,000. Finally, Squarepoint Ops LLC bought a new position in shares of Microbot Medical during the third quarter worth approximately $37,000. Institutional investors and hedge funds own 16.30% of the company’s stock.

Microbot Medical Company Profile

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.